Ranitidine Recall Status: What Patients and Providers Need to Know
pharmacovigilance
Ranitidine recalls emerged after regulators detected unacceptable levels of N-nitrosodimethylamine (NDMA), a probable carcinogen, leading to market withdrawals. This overview ex...
Open article